Drug Profile
Research programme: neurodegenerative disease therapeutics - ProteoTech
Alternative Names: DP-68; DP-74; PD 61 W3; PeptiClere; PTI-19; PTI-51; PTI-51-CH3; Synuclere; TauProLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator ProteoTech
- Class Carbohydrates; Peptides; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
- Discontinued Multiple system atrophy; Progressive supranuclear palsy
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Multiple system atrophy in USA (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Progressive supranuclear palsy in USA (unspecified route)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Multiple system atrophy in USA